191 related articles for article (PubMed ID: 24787714)
41. Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis.
Kincses ZT; Ropele S; Jenkinson M; Khalil M; Petrovic K; Loitfelder M; Langkammer C; Aspeck E; Wallner-Blazek M; Fuchs S; Jehna M; Schmidt R; Vécsei L; Fazekas F; Enzinger C
Mult Scler; 2011 Jun; 17(6):681-9. PubMed ID: 21177325
[TBL] [Abstract][Full Text] [Related]
42. Fatigue and processing speed are related in multiple sclerosis.
Andreasen AK; Spliid PE; Andersen H; Jakobsen J
Eur J Neurol; 2010 Feb; 17(2):212-8. PubMed ID: 19796282
[TBL] [Abstract][Full Text] [Related]
43. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
44. An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol.
Jongen PJ; Heerings M; Ruimschotel R; Hussaarts A; Evers S; Duyverman L; Valkenburg-Vissers J; Cornelissen J; Bos M; van Droffelaar M; Lemmens WA; Donders R; van der Zande A; Visser LH
BMC Neurol; 2016 May; 16():81. PubMed ID: 27234001
[TBL] [Abstract][Full Text] [Related]
45. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
[TBL] [Abstract][Full Text] [Related]
46. Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability.
Migliore S; Ghazaryan A; Simonelli I; Pasqualetti P; Squitieri F; Curcio G; Landi D; Palmieri MG; Moffa F; Filippi MM; Vernieri F
Behav Neurol; 2017; 2017():7404289. PubMed ID: 28912625
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of neuropathic pain in early multiple sclerosis.
Heitmann H; Biberacher V; Tiemann L; Buck D; Loleit V; Selter RC; Knier B; Tölle TR; Mühlau M; Berthele A; Hemmer B; Ploner M
Mult Scler; 2016 Aug; 22(9):1224-30. PubMed ID: 26480924
[TBL] [Abstract][Full Text] [Related]
48. The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis.
Yam C; Merlo D; Stankovich J; Darby D; Gresle M; Kalincik T; Kilpatrick TJ; Lechner-Scott J; Taylor B; Barnett M; Butzkueven H; van der Walt A
Mult Scler Relat Disord; 2020 Aug; 43():102212. PubMed ID: 32474286
[TBL] [Abstract][Full Text] [Related]
49. Brief international cognitive assessment for multiple sclerosis (BICAMS): A danish validation study of sensitivity in early stages of MS.
Marstrand L; Østerberg O; Walsted T; Skov AC; Schreiber KI; Sellebjerg F
Mult Scler Relat Disord; 2020 Jan; 37():101458. PubMed ID: 31683230
[TBL] [Abstract][Full Text] [Related]
50. Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis.
Sundgren M; Maurex L; Wahlin Å; Piehl F; Brismar T
Arch Clin Neuropsychol; 2013 Mar; 28(2):144-55. PubMed ID: 23291310
[TBL] [Abstract][Full Text] [Related]
51. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
[TBL] [Abstract][Full Text] [Related]
52. APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis.
Portaccio E; Goretti B; Zipoli V; Nacmias B; Stromillo ML; Bartolozzi ML; Siracusa G; Guidi L; Federico A; Sorbi S; De Stefano N; Amato MP
Mult Scler; 2009 Dec; 15(12):1489-94. PubMed ID: 19965518
[TBL] [Abstract][Full Text] [Related]
53. Cognitive function in radiologically isolated syndrome.
Lebrun C; Blanc F; Brassat D; Zephir H; de Seze J;
Mult Scler; 2010 Aug; 16(8):919-25. PubMed ID: 20610492
[TBL] [Abstract][Full Text] [Related]
54. Caregiver strain among life partners of persons with mild disability due to relapsing-remitting multiple sclerosis.
van der Hiele K; van Gorp DAM; Heerings MAP; Jongen PJ; van der Klink JJL; Beenakker EAC; van Eijk JJJ; Frequin STFM; van Geel BM; Hengstman GJD; Hoitsma E; Mostert JP; Verhagen WIM; de Gans K; Zemel D; Middelkoop HAM; Visser LH
Mult Scler Relat Disord; 2019 Jun; 31():5-11. PubMed ID: 30877926
[TBL] [Abstract][Full Text] [Related]
55. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
[TBL] [Abstract][Full Text] [Related]
56. Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
van Gorp DAM; van der Hiele K; Heerings MAP; Jongen PJ; van der Klink JJL; Reneman MF; Arnoldus EPJ; Beenakker EAC; van Eijk JJJ; Frequin STFM; de Gans K; Hoitsma E; Mostert JP; Verhagen WIM; Zemel D; Visser LH; Middelkoop HAM
Neurol Sci; 2019 Dec; 40(12):2555-2564. PubMed ID: 31321625
[TBL] [Abstract][Full Text] [Related]
57. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
[TBL] [Abstract][Full Text] [Related]
58. Information processing speed impairment and cerebellar dysfunction in relapsing-remitting multiple sclerosis.
Ruet A; Hamel D; Deloire MS; Charré-Morin J; Saubusse A; Brochet B
J Neurol Sci; 2014 Dec; 347(1-2):246-50. PubMed ID: 25454642
[TBL] [Abstract][Full Text] [Related]
59. Executive function and memory in patients with relapsing-remitting multiple sclerosis.
Cerezo García M; Martín Plasencia P; Aladro Benito Y; Balseiro Gómez JJ; Rueda Marcos A
Psicothema; 2009 Aug; 21(3):416-20. PubMed ID: 19622322
[TBL] [Abstract][Full Text] [Related]
60. Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.
Wickström A; Dahle C; Vrethem M; Svenningsson A
Mult Scler; 2014 Jul; 20(8):1095-101. PubMed ID: 24378984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
